Literature DB >> 21597029

Bone alkaline phosphatase and mortality in dialysis patients.

Christiane Drechsler1, Marion Verduijn, Stefan Pilz, Raymond T Krediet, Friedo W Dekker, Christoph Wanner, Markus Ketteler, Elisabeth W Boeschoten, Vincent Brandenburg.   

Abstract

BACKGROUND AND OBJECTIVES: Serum alkaline phosphatase (AP) is associated with vascular calcification and mortality in hemodialysis patients, but AP derives from various tissues of origin. The aim of this study was to assess the effect of bone-specific AP (BAP) on morbidity and mortality in dialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From a prospective cohort study of incident dialysis patients in The Netherlands, all patients with measured BAP at 12 months after the start of dialysis (baseline) were included in the analysis (n = 800; mean age, 59 ± 15 years; mean BAP = 18 ± 13 U/L). By Cox regression analyses, we assessed the impact of BAP levels on short-term mortality (6 months) and longer-term mortality (4-year follow-up).
RESULTS: High levels of BAP strongly affected short-term mortality. After adjustment for confounders, patients in the highest BAP tertile had a 5.7-fold increased risk of death within 6 months compared with patients in the lowest tertile. The effect applied to both cardiovascular and noncardiovascular mortality. Furthermore, high levels of BAP were associated with increased cardiovascular mortality in the longer term. In comparison with total AP, the effect sizes related to clinical outcomes were much higher for BAP.
CONCLUSIONS: High levels of BAP were strongly associated with short-term mortality in dialysis patients, pointing out the important impact of bone turnover. Longitudinal assessments of BAP may be useful for the treatment monitoring in clinical practice in dialysis patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21597029     DOI: 10.2215/CJN.10091110

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  35 in total

1.  Alkaline phosphatase and mortality in patients on peritoneal dialysis.

Authors:  Xinhui Liu; Qunying Guo; Xiaoran Feng; Juan Wang; Juan Wu; Haiping Mao; Fengxian Huang; Xueqing Yu; Xiao Yang
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

Review 2.  Does PTH offer additive value to ALP measurement in assessing CKD-MBD?

Authors:  Edmund J Lamb; Michael P Delaney
Journal:  Perit Dial Int       Date:  2014 Nov-Dec       Impact factor: 1.756

Review 3.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

Review 4.  The Endocrine Role of Bone in Cardiometabolic Health.

Authors:  Rosemary DeLuccia; May Cheung; Rohit Ramadoss; Abeer Aljahdali; Deeptha Sukumar
Journal:  Curr Nutr Rep       Date:  2019-09

5.  Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.

Authors:  Connie M Rhee; Miklos Z Molnar; Wei Ling Lau; Vanessa Ravel; Csaba P Kovesdy; Rajnish Mehrotra; Kamyar Kalantar-Zadeh
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

6.  Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting.

Authors:  Alex R Chang; Morgan E Grams
Journal:  Am J Kidney Dis       Date:  2014-06-14       Impact factor: 8.860

Review 7.  Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.

Authors:  Usama Elewa; Maria Dolores Sanchez-Niño; Catalina Martin-Cleary; Beatriz Fernandez-Fernandez; Jesus Egido; Alberto Ortiz
Journal:  Int Urol Nephrol       Date:  2012-09-11       Impact factor: 2.370

8.  Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study.

Authors:  Sagar U Nigwekar; Julia Wenger; Ravi Thadhani; Ishir Bhan
Journal:  Am J Kidney Dis       Date:  2013-04-13       Impact factor: 8.860

9.  Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification.

Authors:  Abdul Rashid Qureshi; Hannes Olauson; Anna Witasp; Mathias Haarhaus; Vincent Brandenburg; Annika Wernerson; Bengt Lindholm; Magnus Söderberg; Lars Wennberg; Louise Nordfors; Jonaz Ripsweden; Peter Barany; Peter Stenvinkel
Journal:  Kidney Int       Date:  2015-09-02       Impact factor: 10.612

10.  Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis.

Authors:  Annelie Bergman; Abdul Rashid Qureshi; Mathias Haarhaus; Bengt Lindholm; Peter Barany; Olof Heimburger; Peter Stenvinkel; Björn Anderstam
Journal:  J Nephrol       Date:  2016-03-18       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.